Risk Factors for Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation Using Rabbit Anti-thymocyte Globulin or Porcine Anti-human T Lymphocyte Immunoglobulin in the Letermovir Era.
BACKGROUND Letermovir (LTV) prophylaxis has reduced clinically significant cytomegalovirus (CMV) infection (csCMVi) after allogeneic hematopoietic cell transplantation (allo-HCT). In vivo T-cell depletion is widely used for graft-versus-host disease (GVHD) prevention but is associated with increased risk of CMV infecti...